JP2012522522A - 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物 - Google Patents

志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物 Download PDF

Info

Publication number
JP2012522522A
JP2012522522A JP2012503839A JP2012503839A JP2012522522A JP 2012522522 A JP2012522522 A JP 2012522522A JP 2012503839 A JP2012503839 A JP 2012503839A JP 2012503839 A JP2012503839 A JP 2012503839A JP 2012522522 A JP2012522522 A JP 2012522522A
Authority
JP
Japan
Prior art keywords
stec
protein
fusion protein
proteins
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522522A5 (enExample
Inventor
アンドリュー エイ． ポター
デイヴィッド アスパー
ドラガン ローガン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Telesta Therapeutics Inc
Original Assignee
University of Saskatchewan
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan, Bioniche Life Sciences Inc filed Critical University of Saskatchewan
Publication of JP2012522522A publication Critical patent/JP2012522522A/ja
Publication of JP2012522522A5 publication Critical patent/JP2012522522A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012503839A 2009-04-06 2010-04-06 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物 Pending JP2012522522A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21198909P 2009-04-06 2009-04-06
US61/211,989 2009-04-06
US21660809P 2009-05-19 2009-05-19
US61/216,608 2009-05-19
PCT/CA2010/000516 WO2010115278A1 (en) 2009-04-06 2010-04-06 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015172551A Division JP2016029049A (ja) 2009-04-06 2015-09-02 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物

Publications (2)

Publication Number Publication Date
JP2012522522A true JP2012522522A (ja) 2012-09-27
JP2012522522A5 JP2012522522A5 (enExample) 2013-05-23

Family

ID=42935602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012503839A Pending JP2012522522A (ja) 2009-04-06 2010-04-06 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
JP2015172551A Pending JP2016029049A (ja) 2009-04-06 2015-09-02 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015172551A Pending JP2016029049A (ja) 2009-04-06 2015-09-02 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物

Country Status (7)

Country Link
US (1) US8734811B2 (enExample)
EP (1) EP2417165B1 (enExample)
JP (2) JP2012522522A (enExample)
AU (1) AU2010234193B2 (enExample)
BR (1) BRPI1014505B1 (enExample)
CA (1) CA2757828C (enExample)
WO (1) WO2010115278A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531389A (ja) * 2019-05-01 2022-07-06 イネート バイオロジックス リミテッド ライアビリティ カンパニー 免疫調節用組成物および方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
EP4054655A4 (en) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
US20210369836A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
AR132724A1 (es) 2024-05-17 2025-07-23 Instituto Nac De Tecnologia Agropecuaria Inta Construcción de adn que codifica una proteína de fusión con al menos dos antígenos de escherichia coli enterohemorrágica, vectores, proteína de fusión, métodos de inmunización y vacunas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508301A (ja) * 1990-04-05 1993-11-25 ユニヴァースティ　オブ　サスカチュワン 動物体における肺炎の治療方法および該治療用組成物
JP2001502887A (ja) * 1996-08-09 2001-03-06 ユニバーシティ オブ サスカッチェワン ＧｎＲＨ―ロイコトキシンキメラ
JP2002516875A (ja) * 1998-06-04 2002-06-11 メタモーフィックス，インコーポレイティド 動物の繁殖行動を抑制する方法
JP2004516333A (ja) * 2001-01-04 2004-06-03 ユニバーシティー オブ サスカチェワン 腸管出血性大腸菌ワクチン
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055400A (en) 1986-11-26 1991-10-08 University Of Guelph Leukotoxin gene of pasteurella haemolytica
US4957739A (en) 1987-08-13 1990-09-18 Board Of Regents, The University Of Texas System Pharmaceutical compositions of a 105 kD P. Haemolytica derived antigen useful for treatment of Shipping Fever
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5273889A (en) 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5238823A (en) 1990-08-22 1993-08-24 Veterinary Infectious Disease Organization Interleukin-2-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
AU2699192A (en) 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
ES2389625T3 (es) 1996-04-23 2012-10-29 The University Of British Columbia Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena
EP1029054B1 (en) 1997-11-12 2009-08-05 The University Of British Columbia Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene
US6365723B1 (en) 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
WO2007101337A1 (en) * 2006-03-06 2007-09-13 Bioniche Life Sciences Inc. Methods and compositions comprising bacterial type hi secreted proteins for mucosal immunization of animals
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508301A (ja) * 1990-04-05 1993-11-25 ユニヴァースティ　オブ　サスカチュワン 動物体における肺炎の治療方法および該治療用組成物
JP2001502887A (ja) * 1996-08-09 2001-03-06 ユニバーシティ オブ サスカッチェワン ＧｎＲＨ―ロイコトキシンキメラ
JP2002516875A (ja) * 1998-06-04 2002-06-11 メタモーフィックス，インコーポレイティド 動物の繁殖行動を抑制する方法
JP2004516333A (ja) * 2001-01-04 2004-06-03 ユニバーシティー オブ サスカチェワン 腸管出血性大腸菌ワクチン
WO2004050119A1 (en) * 2002-11-29 2004-06-17 Imperial College Innovations Limited Vaccine against enteropathogenic and enterohaemorragic escherichia coli

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531389A (ja) * 2019-05-01 2022-07-06 イネート バイオロジックス リミテッド ライアビリティ カンパニー 免疫調節用組成物および方法

Also Published As

Publication number Publication date
BRPI1014505A2 (pt) 2016-04-05
EP2417165A4 (en) 2013-02-13
AU2010234193A1 (en) 2011-11-03
US8734811B2 (en) 2014-05-27
JP2016029049A (ja) 2016-03-03
EP2417165A1 (en) 2012-02-15
BRPI1014505A8 (pt) 2017-07-11
WO2010115278A8 (en) 2010-12-02
CA2757828A1 (en) 2010-10-14
BRPI1014505B1 (pt) 2020-02-04
EP2417165B1 (en) 2016-05-25
US20120087939A1 (en) 2012-04-12
AU2010234193B2 (en) 2015-08-20
CA2757828C (en) 2019-01-08
WO2010115278A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
JP5322718B2 (ja) 腸管出血性大腸菌ワクチン
US8697856B2 (en) Plasmodium vivax hybrid circumsporozoite protein and vaccine
JP2016029049A (ja) 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
SK287456B6 (sk) Povrchový proteín Neisseria meningitidis rezistentný voči proteináze K
US20080009022A1 (en) Immunization of dairy cattle with chimeric gapC protein against streptococcus infection
US9267947B2 (en) Compositions and methods for preventing or treating Burkholderia infection
US10946084B2 (en) Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US20230218734A1 (en) Compositions and methods for preventing, controlling and diagnosing mycobacterial infections
WO2017220787A1 (en) Vaccines against aearomonas salmonicida infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150902